Cargando…
Recent Advances in Antiarrhythmic Drug Therapy
Cardiac arrhythmias remain a common cause of death and disability. Antiarrhythmic drugs (AADs) and antiarrhythmic agents remain a cornerstone of current cardiac arrhythmia management, despite moderate efficacy and the potential for significant adverse proarrhythmic effects. Due to conceptual, regula...
Autores principales: | Saljic, Arnela, Heijman, Jordi, Dobrev, Dobromir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462572/ https://www.ncbi.nlm.nih.gov/pubmed/37540446 http://dx.doi.org/10.1007/s40265-023-01923-3 |
Ejemplares similares
-
Emerging Antiarrhythmic Drugs for Atrial Fibrillation
por: Saljic, Arnela, et al.
Publicado: (2022) -
Stretching the limits of antiarrhythmic drug therapy: The promise of small-conductance calcium-activated potassium channel blockers()
por: Heijman, Jordi, et al.
Publicado: (2021) -
Pleiotropic Effects of Antiarrhythmic Agents: Dronedarone in the Treatment of Atrial Fibrillation
por: Heijman, Jordi, et al.
Publicado: (2013) -
TGF-β1–induced endothelial-mesenchymal transition: a potential contributor to fibrotic remodeling in atrial fibrillation?
por: Saljic, Arnela, et al.
Publicado: (2022) -
Botulinum toxin for prevention of post-operative atrial fibrillation
por: Saljic, Arnela, et al.
Publicado: (2023)